Skip to search formSkip to main contentSkip to account menu

tirofiban

Known as: Tirofibanum, tirofiban [Chemical/Ingredient], N-(butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine 
National Institutes of Health

Related topics

Related topics

21 relations
15 ML tirofiban 0.25 MG/ML Injection [Aggrastat]AneurysmAngina, UnstableCongenital arteriovenous malformation

Narrower (5)

AggrastatL 700462MK 383TIROFIBAN HYDROCHLORIDE

Broader (3)

Fibrinolytic AgentsPlatelet Aggregation InhibitorsTyrosine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Intra-arterial infusion of tirofiban and urokinase for thromboembolic complications during coil embolization of ruptured intracranial aneurysms.
AIM To investigate the effectiveness and safety of intra-arterial tirofiban and urokinase for thromboembolic complications during… 
2013
2013
[The prospective register study of domestic tirofiban for clinical application in acute coronary syndrome].
OBJECTIVE To evaluate the current clinical application of domestic tirofiban in patients with acute coronary syndrome (ACS) and… 
2010
2010
Two-Year Follow-Up of Tirofiban-Based Management of Non-ST-Elevation Acute Coronary Syndrome-A Single Center Study
Background: The current practice guidelines suggest early and invasive strategies in treating patients of non ST-elevation acute… 
2006
2006
Increased ability of tirofiban to maintain its inhibitory effects on the binding of fibrinogen to platelets in blood from patients with and without diabetes mellitus
ObjectivesBoth tirofiban and eptifibatide release rapidly from glycoprotein IIb–IIIa but have different dissociation constants… 
2005
2005
Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers
Anticoagulant andanti-platelet effectsare maintained following coadministration of otamixaban, adirect factor Xa inhibitor, with… 
2005
2005
Nonalcoholic fatty liver and insulin resistance among petrochemical workers.
1. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and… 
2004
2004
Myocardial infarction with intracoronary thrombus induced by anabolic steroids.
The use of anabolic steroids has been increased among strength trainers. Unfortunately, they are associated with adverse effects… 
Review
2001
Review
2001
Platelet Aggregation Inhibition with Glycoprotein IIb–IIIa Inhibitors
Inhibitors of the platelet receptor glycoprotein (GP) IIb–IIIa are a novel and potent class of antithrombotic drugs for the… 
2000
2000
High Platelet Count in Platelet-Rich Plasma Reduces Measured Platelet Inhibition by Abciximab but not Tirofiban nor Eptifibatide Glycoprotein IIb/IIIa Receptor Antagonists
We evaluated the differential effect of platelet count in platelet-rich plasma (PRP) on the level of ex vivo inhibition of… 
Review
1998
Review
1998
Safety and effectiveness of inhaled nitric oxide and tirofiban for acute coronary syndromes: a report from the cardiovascular and renal advisory panel of the food and drug administration.
The Cardiovascular and Renal Advisory Panel of the Food and Drug Administration (FDA) met April 9 to 10, 1998, to discuss the…